Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$15.97 USD
-0.20 (-1.24%)
Updated May 20, 2024 04:00 PM ET
After-Market: $16.01 +0.04 (0.25%) 6:30 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
DAWN 15.97 -0.20(-1.24%)
Will DAWN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DAWN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DAWN
Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More
Here's What Could Help Day One Biopharmaceuticals, Inc. (DAWN) Maintain Its Recent Price Strength
DAWN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a Bet
Biotech ETF Tops in June: 5 Stocks That Outperform
Other News for DAWN
BrightSpring Health announces Onco360 selected as partner for OJEMDA
Bank of America Securities Reaffirms Their Sell Rating on Day One Biopharmaceuticals (DAWN)
Analysts’ Top Healthcare Picks: Viridian Therapeutics (VRDN), Day One Biopharmaceuticals (DAWN)
Buy Rating for Day One Biopharmaceuticals Amidst DAY101 Approval and Strong Market Entry
Buy Rating on Day One Biopharmaceuticals: Ojemda’s Market Potential and Strategic Commercialization